Abstract
Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent self-limited attacks of fever and polyserositis. Reactive amyloid A amyloidosis is the most devastating complication of FMF, and amyloidosis continues to occur in the colchicine era in untreated and noncompliant patients. Unfortunately, there is no proven effective treatment for established amyloidosis. In this report, we present four FMF-related amyloidosis patients that were treated with long term infliximab therapy with the longest duration of follow-up, together with the literature review. Infliximab was very effective in controlling gastrointestinal system findings and protracted arthritis, and it also had a favorable impact on the clinical findings of nephrotic syndrome in these patients. In conclusion, by controlling debilitating complaints of amyloidosis with infliximab, quality of life increases in these patients, and they get rid of recurrent hospitalizations and return to school or work.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lidar M, Livneh A (2007) Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med 65:318–324
Mamou H, Cattan R (1952) La maladie periodique (sur 14 cas personnels dont 8 compliques de nephropathies). Sem Hop Paris 28:1062–1070
Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287:1302
Özkan E, Okur Ö, Ekmekçi A, Özcan R, Tağ T (1972) A new approach to the treatment of periodic fever. Med Bull Istanbul 5:44–49
Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F et al (2005) Familial Mediterranean fever (FMF) in Turkey. Results of nationwide multicenter study. Medicine 84:1–11
Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D et al (2007) Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 56:1706–1712
Cakar N, Yalçinkaya F, Ozkaya N, Tekin M, Akar N, Koçak H et al (2001) Familial Mediterranean fever (FMF)-associated amyloidosis in childhood. Clinical features, course and outcome. Clin Exp Rheumatol 5(Suppl 24):S63–S67
Sayarlıoğlu H, Erkoç R, Sayarlıoğlu M, Dogan E, Soyoral Y (2006) Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish case. Rheumatol Int 27:197–199
Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR (2004) Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol 10:134–137
Yüksel S, Yalçınkaya F, Acar B, Özçakar ZB, Öztürk B, Ekim M (2006) Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology 45:1307–1321
Bodur H, Seçkin Ü, Eser F, Ergül G, Seçkin S (2008) Coexistence of familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy. Rheumatol Int 29:107–110
Erten S, Erten SF, Altunoğlu A (2012) Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial Mediterranean fever (FMF) resistant to colchicine:anti-TNF drugs and FMF. Rheumatol Int 32:1095–1097
Özgöçmen S, Akgül Ö (2011) Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature. Mod Rheumatol 21:684–690
Dember LM, Hawkins PN, Hazenberg BPC, Gorevic PD, Merlini G, Butrimiene I et al (2007) Eprodisate for the treatment of renal disease in AA amyloidosis. N Eng J Med 356:2349–2360
Gafni J, Ravid M, Sohar E (1968) The role of amyloidosis in familial Mediterranean fever. A population study. Isr J Med 4:995–999
Fl Ö, Kaplaman E, Zileli S (1971) Familial Mediterranean fever in Turkey. A report of twenty cases. Am J Med 50:336–339
Falk RH, Comenzo RL, Skinner M (1997) The systemic amyloidoses. N Eng J Med 337:898–909
Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7:64–69
Levalampi T, Honkanen V, Lahdenne P, Nieminen R, Hakala M, Moilanen E (2007) Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand J Rheumatol 36:189–193
Özgöçmen S, Özçakar L, Ardıçoğlu Ö, Kocakoç E, Kaya A, Kiriş A (2006) Familial Mediterranean fever responds well to infliximab:single case experience. Clin Rheumatol 25:83–87
Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002) Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis & Rheumatism 46:2571–2573
Pettersson T, Konttinen YT, Maury CPJ (2008) Treatment strategies for amyloid A amyloidosis. Expert Opin Pharmacother 9:2117–2128
Dember LM (2006) Amyloidosis associated kidney disease. J Am Soc Nephrol 17:3458–3471
Kuroda T, Wada Y, Kobayashi D, Murakami S, Sakai T, Hirose S et al (2009) Effective anti-TNF-α therapy can induce rapid resolution and sustained decrease of gastroduedenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol 36:2409–2415
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Özçakar, Z.B., Yüksel, S., Ekim, M. et al. Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up. Clin Rheumatol 31, 1267–1271 (2012). https://doi.org/10.1007/s10067-012-2009-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-012-2009-1